Conference Coverage

ctDNA Monitoring of Patients With ER-Positive, HER2-Negative High Risk Breast Cancer During Adjuvant Endocrine Therapy

Featuring Lajos Pusztai, MD, DPhil

01/03/2024

Lajos Pusztai, MD, DPhil, Yale Cancer Center, New Haven, Connecticut,discussed results from the DARE study which analyzed the clinical utility of ctDNA monitoring during adjuvant endocrine therapy to detect molecular relapse before apparent recurrence.

These results were first reported at the 2023 San Antonio Breast Cancer Symposium.

Source:

Pusztai L, Kalashnikova E, Hobbs E, et al. Circulating tumor DNA (ctDNA) monitoring of estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) high risk breast cancer during adjuvant endocrine therapy. Presented at the 2023 San Antonio Breast Cancer Symposium; December 5-9; San Antonio, Texas. Abstract PS06-02

© 2023 HMP Global. All Rights Reserved.

Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.

Recent News

News

First-Line Pembrolizumab Plus Chemotherapy Showed Promise Among Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

07/26/2024

Stephanie Holland ;

According to results from the KEYNOTE-B10 trial, first-line pembrolizumab plus carboplatin and paclitaxel showed promising antitumor activity with manageable safety among patients with recurrent or metastatic head and neck squamous cell...

According to results from the...

07/26/2024

Oncology

News

Potential for Shorter Monitoring Period for Patients With R/R MM Following CAR-T Therapy

07/26/2024

Amber Denham ;

A shorter monitoring period may be reasonable for patients with relapsed/refractory multiple myeloma who underwent CAR-T therapy following results that suggest a low risk of cytokine release syndrome and immune effector cell-associated...

A shorter monitoring period may...

07/26/2024

Oncology

News

Utilizing T-Cell Assays in Diagnosing Familial Hemophagocytic Lymphohistiocytosis and Defects in Lymphocyte Exocytosis

07/25/2024

Amber Denham ;

According to a prospective analysis, a combined use of TCR-triggered T-cell and FcR-triggered NK-cell exocytosis assays demonstrated efficacy in diagnosing familial hemophagocytic lymphohistiocytosis and defects in lymphocyte exocytosis.

According to a prospective...

07/25/2024

Oncology

News

SHR-A1811 Showed Promise Among Patients With HER2-Expressing Solid Tumors

07/25/2024

Stephanie Holland ;

According to results from a first-in-human, phase 1 study, SHR-A1811 demonstrated promising antitumor activity with acceptable safety and tolerability among heavily pretreated patients with HER2-expressing or mutated advanced solid tumors.

According to results from a...

07/25/2024

Oncology

News

Brentuximab Vedotin and Ibrutinib Combination Fails to Provide Safety Among Patients With R/R Hodgkin Lymphoma

07/23/2024

Amber Denham ;

According to results from a phase 2 trial, brentuximab vedotin and ibrutinib therapy demonstrated activity among patients with R/R Hodgkin lymphoma, however the combination cannot be recommended for future therapeutic development due to...

According to results from a...

07/23/2024

Oncology

News

Combined Low-Dose Ruxolitinib and Emapalumab Treatment Demonstrates Efficacy for Patients With Hemophagocytic Lymphohistiocytosis

07/23/2024

Gina Tomaine ;

The combination of low-dose ruxolitinib and anti-interferon-gamma antibody emapalumab demonstrated efficacy and safety for treating patients with hemophagocytic lymphohistiocytosis, according to a retrospective analysis.

The combination of low-dose...

07/23/2024

Oncology

News

Analyzing Real-World Outcomes of Emapalumab Treatment for Patients With Primary Hemophagocytic Lymphohistiocytosis

07/23/2024

Gina Tomaine ;

According to retrospective study REAL-HLH, the real-world clinical efficacy, patterns, and survival outcomes of emapalumab treatment among patients with primary hemophagocytic lymphohistiocytosis were consistent with the results a pivotal...

According to retrospective study...

07/23/2024

Oncology

News

Maintenance Selinexor Showed Promise for Patients With Advanced or First-Line Recurrent TP53 Wild-Type Endometrial Cancer

07/23/2024

Stephanie Holland ;

Subgroup analysis results from the phase 3 SIENDO study found selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer.

Subgroup analysis results from...

07/23/2024

Oncology

News

Dostarlimab Plus Chemotherapy as New Standard of Care for Patients With Primary Advanced or Recurrent Endometrial Cancer

07/22/2024

Stephanie Holland ;

Second interim analysis results from the phase 3 RUBY trial demonstrated that the addition of dostarlimab to chemotherapy improved overall survival among patients with primary advanced or recurrent endometrial cancer.

Second interim analysis results...

07/22/2024

Oncology

News

First-Line Amivantamab Plus Lazertinib Superior to Osimertinib Among Patients With Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

07/18/2024

Stephanie Holland ;

Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.

Results from the phase 3...

07/18/2024

Oncology